Insmed (MEX:INSM) Payments of Debt: MXN-57 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INSM Insmed Inc MEX:INSM
73 GF Score
Price MXN2,135.00
GF Value MXN3,415.35
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Payments of Debt?

Insmed MEX:INSM +26.33% 73 Payments of Debt is MXN-57 Mil as of Jun. 2026. GuruFocus rates MEX:INSM with a GF Score™ of 73/100 and a GF Value™ of MXN3,415.35 (Possible Value Trap). The stock has 4 warning signs investors should review.

Insmed's Payments of Debt for the three months ended in Jun. 2026 was MXN-14 Mil.

Insmed's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-57 Mil.

Insmed Payments of Debt Related Terms

Insmed Payments of Debt Historical Data

* Premium members only.

The historical data trend for Insmed's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Payments of Debt Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,895.85 -11.72 -20.66 -54.43 -88.70

Insmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.78 -13.70 -13.97 -14.41 -14.43
MEX:INSM
73GF Score
Insmed Inc MEX:INSM
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of MXN-57 Mil mean?
Insmed (MEX:INSM) has a Payments of Debt of MXN-57 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Insmed and its competitors.
Is Insmed's Payments of Debt too high?
Insmed's current Payments of Debt is MXN-57 Mil. Overall, Insmed has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Payments of Debt compare to INCY and BNTX?
Insmed's Payments of Debt of MXN-57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Insmed and its competitors. Insmed's current Payments of Debt is MXN-57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MEX:INSM) is currently considered Possible Value Trap. The stock's GF Value™ is MXN3,415.35, compared to a current price of MXN2,135.00 — trading 37.5% below its estimated fair value. The current Payments of Debt is MXN-57 Mil. Insmed's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Payments of Debt is MXN-57 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (MEX:INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of MXN2,135.00 is trading 37.5% below its estimated GF Value™ of MXN3,415.35. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for MEX:INSM:

  • Payments of Debt: MXN-57 Mil
  • GF Value™: MXN3,415.35 vs. price of MXN2,135.00 (37.5% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
73GF Score

Get the complete analysis for MEX:INSM

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,135.00
Price
MXN3,415.35
GF Value